🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Truro
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Truro

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 99 Manchester 39 Cambridge 26 Glasgow 23 Bristol 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC16 Regeneron Pharmaceuticals6 AstraZeneca6 Pfizer5 Janssen Research & Development, LLC3 Clear sponsor filter
Site city
London99 Manchester39 Cambridge26 Glasgow23 Bristol17
All 91 cities
Target enrolment
to
16 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
675
Truro, London, Birmingham, Leicester
2025-10-08
Recruiting
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 2
250
East Sussex, Truro, London, Edinburgh, Birmingham, Manchester
2025-08-11
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Truro, London, Nottingham, Taunton, Birmingham, Cardiff, Leeds
2025-03-16
Active, closed
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT06428396Metastatic Breast Cancer
Merck Sharp & Dohme LLC
Phase 2
120
Truro, London, Withington, Ipswich
2024-11-27
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
67
Torquay, Truro
2024-11-21
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,530
Bristol, Truro, London, Edinburgh, Leeds
2024-06-24
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,200
Londonderry, Truro, London, Blackpool, Nottingham
2024-04-14
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
Merck Sharp & Dohme LLC
Phase 3
1,310
Cambridge, Truro, Glasgow, London, Manchester
2023-12-31
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Cambridge, Derby, Torquay, Northwood, Truro, Glasgow, London, Oxford
2023-12-18
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
East Sussex, Derby, London, Truro, Glasgow, Manchester
2023-12-06
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Truro, London, Oxford, Manchester
2022-07-21
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC
Phase 2/3
290
Aberdeen, Truro, London-Camden
2022-01-14
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Merck Sharp & Dohme LLC
Phase 3
643
East Sussex, Cambridge, Truro, Kendal, Dundee, Leicester, London, Cardiff
2021-12-13
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
342
Truro, Leicester, London, Manchester, Blackpool, Londonderry
2021-06-18
Active, closed
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895Urinary Bladder Cancer, Muscle-invasive
Merck Sharp & Dohme LLC
Phase 3
595
Walsall, Canterbury, Middlesbrough, London, Stevenage, Edinburgh, Metropolitan Borough of Wirral, Truro
2019-07-24
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,240
Bristol, Nottingham, Colchester, London, Solihull, Truro
2018-12-27
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/truro

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.